Free Trial
NASDAQ:FBRX

Forte Biosciences Q1 2026 Earnings Report

Forte Biosciences logo
$24.63 -1.37 (-5.28%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Forte Biosciences EPS Results

Actual EPS
-$1.24
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Forte Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Forte Biosciences Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Forte Biosciences' Q2 2026 earnings is estimated for Thursday, May 21, 2026, based on past reporting schedules

Forte Biosciences Earnings Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More Forte Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email.

About Forte Biosciences

Forte Biosciences (NASDAQ:FBRX) is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis. FB-401 has shown promise in early studies for reducing inflammation and improving barrier function, and is currently being evaluated in Phase 2 clinical trials. In addition to atopic dermatitis, Forte is exploring pipeline opportunities in rare genetic skin conditions such as epidermolysis bullosa, where reinforcing the skin’s protective barrier is a critical unmet need.

Forte Biosciences conducts clinical research across North America and Europe, collaborating with academic institutions and patient advocacy groups to accelerate development timelines. The company’s management team comprises professionals with extensive experience in biotechnology R&D, regulatory affairs, and commercial strategy, positioning Forte to translate scientific discoveries into potential therapeutic options for patients with chronic and rare skin disorders.

View Forte Biosciences Profile